VALN News and Press, Valneva SE From 05/09/22

The following slide deck was published by Valneva SE in conjunction with their 2022 Q1 earnings call. For further details see: Valneva SE 2022 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. Valneva SE (NASDAQ: VALN) Q1 2022 Earnings Call May 05, 2022 , 9:00 a.m. ET Operator Continue reading For further details see: Valneva SE (VALN) Q1 2022 Earnings Call Transcript

Valneva press release (NASDAQ:VALN): Q1 net loss of €26.0 million compared to a net loss of €27.7 million in the first quarter of 2021 Revenue of €21.8M (-6.0% Y/Y). Adjusted EBITDA loss in the first quarter of 2022 was €12.7 million compared to an EBITDA...

Over the past few years, popular pharmaceutical company Pfizer (NYSE: PFE) has proven to be a resilient stock during market downturns. That happened on Tuesday when the shares eked out a slight gain as the S&P 500 suffered a nearly 3% decline. Investors were cheered by some ...

Strong immunogenicity profile observed in study participants aged 5-17 years one month after the primary vaccination series Safety profile observed in pediatric participants similar to previously reported data in adult participants Pediatric population to b...

Pfizer (NYSE:PFE) Valneva (NASDAQ:VALN) said they plan to include children above 5 years of age in a planned phase 3 trial of their Lyme disease vaccine VLA15 after positive pediatric data was reported from a phase 2 trial, which included children aged 5 years to 17 years, amon...

The ADRs of Valneva (NASDAQ:VALN) have lost ~17% in the premarket Monday after the French biotech announced on Monday that the European Medicines Agency (“EMA”) requested additional data to support the marketing authorization for the company’s COVID-19 vaccine V...

Are These The Best Health Care Stocks To Buy As Pandemic Conditions Worsen? Between an increasingly aggressive Fed interest rate hike plan, ongoing pandemic conditions, and inflation, the stock market is under pressure. As a result of all this, investors could be turning their a...

Headed into a three-day holiday weekend, stocks lost ground on Thursday, reversing an attempted recovery posted in the previous session. Tech stocks led the retreat, contributing to a 2.1% slide in the Nasdaq. Drug development news provided a significant catalyst during the session. Valneva (...

Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...